OHE Consulting

Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential drawbacks, and considerations for implementation. We then ask for your views. To submit your thoughts, please access the survey which accompanies the Discussion Paper. Consultation closing date: Monday 24th June 2019.

Just published is a new OHE Consulting Report that explores society’s preferences across curative and non-curative therapies and large and small health gains.

This year, the OHE team published 39 peer reviewed journal articles, gave 58 lectures and conference presentations, posted 22 in-house OHE publications on our website, and hosted 6 lunchtime seminars and our annual lecture.

OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.

OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.

This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.

OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.

OHE Consulting has produced a report summarising the literature on indication-based pricing and how it has been applied in the U.S. and 5 European countries.

A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.

OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector.

Pages

Subscribe to RSS - OHE Consulting